Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04216017 · ClinicalTrials.gov registry record · Phase 2
Glenohumeral Cortisone Injection
A Phase 2 study of Humeral Fractures, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04216017 is a Phase 2 study of Humeral Fractures that has completed, run by University of Washington. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04216017, a Phase 2 study of Humeral Fractures, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.
Conditions Studied
Interventions
- DRUG Lidocaine
- DRUG kenalog
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2022-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04216017
The ClinicalTrials.gov registry entry for NCT04216017 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Humeral Fractures appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine is the first listed.
NCT04216017 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04216017 about?
NCT04216017 is a clinical study titled "Glenohumeral Cortisone Injection". The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.
What is the current status of trial NCT04216017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-01-01. Estimated completion is 2022-05-01.
What conditions does trial NCT04216017 study?
This clinical trial studies the following conditions: Humeral Fractures.
What interventions are being tested in trial NCT04216017?
The interventions under investigation include: Lidocaine (DRUG), kenalog (DRUG).
Who is sponsoring clinical trial NCT04216017?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04216017 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Humeral Fractures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.